The QualityStocks Daily Friday, November 1st, 2019

Today's Top 3 Investment Newsletters

StreetInsider (CRC) +50.09%

QualityStocks (ESMC) +45.43%

StockMarketWatch (CHFS) +39.13%

The QualityStocks Daily Stock List

Abacus Health Products, Inc. (ABAHF)

New Cannabis Ventures, BioSpace, Stockwatch, InvestorX, Market Wire News, Dividend Investor, PR Newswire, Market Screener, Seeking Alpha, TradingView, Stockhouse and Investing.com reported previously on Abacus Health Products, Inc. (ABAHF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Abacus Health Products, Inc. engages in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and that contain organic and natural ingredients. This includes a cannabinoid-rich hemp extract containing CBD (cannabidiol) from the Cannabis sativa L plant. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC. Abacus Health Products lists on the OTC Markets’ OTCQX.

Abacus Health Products established in 2014 with the mission to use advanced topical formulations that combine CBD hemp extract (Cannabis sativa L.) with leading topical analgesics (menthol and camphor) to deliver temporary pain relief products to millions of people worldwide. In 2016, the Company started distribution to healthcare practitioners under the CBD CLINIC brand name. Because of premier effectiveness, CBD CLINIC products quickly became the #1 preferred external analgesics for thousands of practitioners throughout the United States. In Q3 2018, Abacus launched CBDMEDIC directly to the active fitness and mass retail marketplaces.

Abacus Health Products is the first international company to develop, brand, and sell OTC topical medications blended with authorized pharmaceutical active ingredients and legal hemp extract. The Company’s CBD CLINIC is sold exclusively to licensed health practitioners. CBDMEDIC is sold directly to consumers through retail pharmacies, fitness centers, and also manifold e-commerce platforms.

Abacus Health Products’ proprietary formulations are applied topically to treat the pain at the source of the problem. This is in comparison to oral medications that are absorbed by the entire body and may have serious side effects. The Company designed its formulations to combine a proprietary blend of natural emollients that facilitate deep and fast absorption of pain-relieving analgesic compounds, and powerful, naturally derived terpenes (aromatic oils and analgesic compounds) to temporarily reduce pain.

This week, Abacus Health Products announced that an additional major national retail pharmacy chain in the U.S. will be offering products from its CBDMEDIC product line. The expectation is that the products will launch into 1,300 of the chain’s retail locations across the U.S. The chain will be adding three innovative products from the CBDMEDIC product line to its shelves. These are Muscle & Joint Pain Relief Spray, Arthritis Aches & Pain Relief Ointment, and Back & Neck Pain Relief Ointment. The products are planned to be rolled-out in December of this year.

Abacus Health Products, Inc. (ABAHF), closed Friday's trading session at $4.50, off by 5.0633%, on 2,735 volume with 27 trades. The average volume for the last 3 months is 15,092 and the stock's 52-week low/high is $3.00/$14.00.

chart

Diversicare Healthcare Services, Inc. (DVCR)

Zacks, Stock Twits, Glassdoor, TradingView, Stockwatch, Morningstar, MacroTrends, Street Insider, TipRanks, TMXmoney, Market Screener, Stockhouse, Simply Wall St, Morningstar, PR Newswire, Dividend.com, Nasdaq, Investing.com, GuruFocus, 4-Traders, Seeking Alpha, and GlobeNewswire reported earlier on Diversicare Healthcare Services, Inc. (DVCR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Diversicare Healthcare Services, Inc. provides post-acute care services to skilled nursing center, patients, and residents mainly in the Southeast, Midwest, and Southwest United States. As of September 4, 2019, the Company provides long-term care services to patients in 62 skilled nursing and senior housing centers containing 7,329 licensed nursing beds. OTCQX-listed, Diversicare Healthcare Services is based in Brentwood, Tennessee.

The Company’s centers have a comprehensive team trained to administer high quality healthcare. This includes short term rehabilitation, complex medical care, long term care, or memory care. Diversicare’s dedication is to providing a comfortable, homelike environment while offering front-line activities and therapies.

Diversicare Healthcare Services provides therapy powered by Diversicare Therapy Services (DTS). Its emphasis is a specialized team of therapists that share it mission and core values and also its passion for providing ground-breaking healthcare solutions. At DTS, its team of therapists create customized rehabilitation programs based on an individual’s needs. In addition, in numerous centers, DTS offers outpatient services provided by the same therapists that assisted one in getting home.

Yesterday, Diversicare Healthcare Services announced its results for Q3 ended September 30, 2019. Highlights include a Net Loss from Continuing Operations of $1.9 million, or $0.30 per share, versus a Net Loss from Continuing Operations of $7.5 million, or $1.17 per share, in Q3 of 2018. Diversicare completed its exit from the State of Kentucky effective on August 30, 2019 that consisted of 13 centers and 1,127 skilled nursing beds.

The Company’s Adjusted EBITDAR for the quarter was $14.4 million. It defines Adjusted EBITDAR as Adjusted EBITDA adjusted for rent expense.

Mr. Jay McKnight, President and Chief Executive Officer of Diversicare Healthcare Services, said, "This quarter we successfully completed the exit of operations in the State of Kentucky, which is the latest of our larger initiatives. Over the past year we have undertaken major steps to improve our clinical offerings and risk profile, renew our largest operating lease, improve our operating cost structure, and work through our open government matter.”

Diversicare Healthcare Services, Inc. (DVCR), closed Friday's trading session at $2.705, even for the day, on 2 volume with 1 trade. The average volume for the last 3 months is 8,078 and the stock's 52-week low/high is $1.15999996/$2.99.

chart

Manganese X Energy Corp. (SNCGF)

Bull Market News, Ahead of the Herd, Market Screener, Geology for Investors, Investing News, Stockhouse, InvestorIntel, 4-Traders, The Prospector, Mining Stock Education, Oil & Gas 360, StreetWise Reports, Stockwatch, and Wallet Investor reported earlier on Manganese X Energy Corp. (SNCGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Manganese X Energy Corp.’s mission is to acquire and advance high potential manganese mining prospects in North America. Its intention is to supply value added materials to the lithium ion battery and other alternative energy industries. Manganese dioxide is an important element in the manufacture of the most promising kinds of Lithium Ion batteries. These kinds of batteries are the most promising because of their superior storage capacity, safety, as well as cost. The Company earlier went by the name Sunset Cove Mining, Inc. It changed its corporate name to Manganese X Energy Corp. in December of 2016. Manganese X Energy is based in Saint-Laurent, Quebec.

Manganese X Energy has created a standalone subsidiary within the parent Company named Disruptive Battery Corp. It has secured the domain batterydisruptors.com. The new company was created to speed up a manganese thesis as it relates to fuel cells and stored energy. The intention is to advance the movement of manganese for greener power production and penetrating the EV (Electric Vehicle) market.

Manganese X Energy’s plan is to provide a secure ethically sourced manganese supply by exploring and developing its manganese rich deposit near Woodstock, New Brunswick (Battery Hill Project). The Battery Hill property comprises 55 claims totaling 1,228 hectares located in Carlton County, New Brunswick. The project encompasses all or part of five manganese zones - Iron Ore Hill, Moody Hill, Sharpe Farm, Wakefield and Maple Hill.

Manganese X Energy also has its Peter Lake Property. Peter Lake consists of 34 claims totalling about 1985 Ha situated in the Mont-Laurier Terrane, in the Central Grenville Province, Quebec. Two Copper-Nickel-Cobalt Occurrences called Peter Lake North and Peter Lake South are included within the Property. Previous grab sampling returned values ranging from 0.4 percent to 22.8 percent copper, 0.14 percent to 0.73 percent nickel, 500 ppm to 0.266 percent cobalt, as well as elevated gold and silver.

Last week, Manganese X Energy announced that it received an encouraging update from Kemetco Research, Inc. who is developing a commercializable flow sheet to produce ultra high-purity (greater than 99.9 percent) battery-grade manganese for the growing electric vehicle and energy storage sectors. As earlier disclosed from Manganese X’s Battery Hill property in New Brunswick a 99.60 percent MnSO4 product has been produced. The goal of this phase of the project is to further enhance the purity and produce sufficient samples for marketing purposes.

Manganese X Energy Corp. (SNCGF), closed Friday's trading session at $0.061, even for the day, on 27,000 volume. The average volume for the last 3 months is 980 and the stock's 52-week low/high is $0.061/$0.133000001.

chart

MariMed, Inc. (MRMD)

PotStockNews, Morningstar, Profit Confidential, Micro Small Cap, Trading View, NIC Investors, Equity Clock, Daily Marijuana Observer, Stock of the Week, CannabisNewsWire, CannabisMarketCap, Super Stock Screener, The Cannabis Investor.ca, Wallet Investor, Market Screener, and Stockhouse reported beforehand on MariMed, Inc. (MRMD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MariMed, Inc. is a top multi-state cannabis operator centered on health and wellness. The Company’s commitment is to improving health and wellness with the highest quality hemp and cannabis products. It offers a complete range of cannabis products and operates state-of-the-art cannabis dispensaries in six States. Furthermore, MariMed has a separate division, MariMed Hemp, centered on the development of industrial hemp-derived CBD (cannabidiol) products. MariMed has its corporate office in Norwood, Massachusetts. The Company’s shares trade on the OTC Markets’ OTCQX.

MariMed is a first mover into the hemp CBD market. It has supply and products in the United States and the European Union (EU). MariMed’s emphasis is the continuing discovery of better wellness via cannabis and hemp. Its platform consists of a vertically integrated approach.

MariMed holds 13 cannabis licenses for cultivation, production and dispensaries across 6 U.S. States. It is presently managing greater than 300,000 square feet of premier cannabis facilities. The Company also supports research and physician education, supported by the Scientific Advisory Board.

Regarding Seed-to-Sale, the Company has wide-ranging experience with the broad array of issues relevant to legal cannabis business activities. This includes licensing for cultivation, processing and dispensing, litigation, banking and finance, raising and deploying capital, protecting intellectual property (IP), real estate development and leasing, and additional clickthroughs.

Concerning its brands and products, MariMed begins with a quality growing medium, rich genetics, and natural nutrients to formulate products for differing speeds and methods of delivery. Its products always include a broad variety of dosing preferences and rich terpene profiles.

Last week, MariMed announced it signed a definitive agreement to license its market leading brands and products, Betty’s Eddies™ and Kalm Fusion™, to Tropizen of Puerto Rico. Moreover, MariMed will become a licensee to manufacture and distribute Tropizen’s innovative tropical products, Pique hot sauce and Real Fruit Gummies in the six States that MariMed serves in the United States. The companies are in final review of production requirements to set launch dates for each product by territory.

Yesterday, MariMed announced that its Chief Innovation Officer, Dr. Jokūbas Žiburkus, spoke at the European American Cannabis Business Conference in Prague on October 31, 2019. The discussion was the first of numerous forthcoming talks the renowned scientific innovation and thought leader will be presenting on the topics of CBG (cannabigerol), known as “the mother of all cannabinoids.” Dr. Jokūbas Žiburkus is an award-winning professor of neuroscience.

MariMed, Inc. (MRMD), closed Friday's trading session at $0.98, off by 2.00%, on 351,449 volume with 317 trades. The average volume for the last 3 months is 762,769 and the stock's 52-week low/high is $0.654999971/$5.32999992.

chart

Recruiter.com Group, Inc. (RCRT)

Zacks, StreetWise Reports, TipRanks, Proactive Investors, Last10k, OTC Markets, GlobeNewswire, Nasdaq, Investors Hangout, Dividend.com, Simply Wall St, InvestorsHub, Stockhouse, Stockwatch, MarketWatch, GuruFocus, TradingView, Market Screener, and Morningstar reported previously on Recruiter.com Group, Inc. (RCRT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

An expert network for recruiters, Recruiter.com Group, Inc. is a leading platform connecting recruiters and employers. The Company pairs enterprises with a broad network of recruiters and powerful AI (Artificial Intelligence) matching tools to foster the hiring of premier talent faster and smarter. Recruiter.com offers recruiters SHRM certified recruitment training and independent earning opportunity. The Company provides enterprise and mid-market employers recruiting services designed to scale across a diverse range of skills and industries. OTCQB-listed, Recruiter.com Group has its headquarters in Houston, Texas and additional offices in Bristol, Connecticut, and Ebene, Mauritius.

The design of Recruiter.com Group’s business is to accelerate recruiting and hiring success via technology adoption. Its primary product and service is its cloud-based “Job Market” software platform for professional hiring. The Job Market software facilitates connections to a nationwide network of professional recruiters.

In addition, the Job Market software is augmented by proprietary AI technologies that draw from talent communities of millions of people. Recruiter.com provides employers a flexible, performance-based hiring model for permanent and contract talent. The Company has strategic partnerships in numerous areas of the recruitment process. These include AI candidate matching software, applicant tracking systems, job sites, resume writing and career services, recruitment and career content providers, and recruitment service and outsourcing firms.

Recently, Recruiter.com Group announced the launch of its Recruiter Teams solution for its enterprise clients. The Recruiter.com platform now automates the building of dedicated teams of recruiters to interact with particular clients for quicker turnaround of candidates with high quality. The Recruiter.com Job Market platform fills jobs for employers by distributing jobs to its network of more than 11,000 recruiters. Through referring candidates to these jobs, independent recruiters have the opportunity to drive considerable earnings by making successful placements, and receiving other incentives, including Recruiter Reward Points.

In October, Recruiter.com Group announced a partnership agreement with Geometric Results, Inc. (GRI), a subsidiary of MSX International, the world’s largest independent non-employee workforce solutions provider. GRI’s vendor neutral ownership provides an equal platform for GRI’s talent providers and positions GRI’s innovation in talent acquisition, direct sourcing, as well as data analytics.

GRI maintains a conflict-free position regarding staffing suppliers and VMS technology platforms. Its solution includes management of clients’ non-employee labor population from contracting, to supplier management, payment services, and advanced analytics.

Recruiter.com Group, Inc. (RCRT), closed Friday's trading session at $1.175, even for the day, on 1 volume with 1 trade. The average volume for the last 3 months is 5,204 and the stock's 52-week low/high is $0.782000005/$18.3999996.

chart

Second Sight Medical Products, Inc. (EYES)

Zacks, Stock Twits, Nasdaq, MacroTrends, TMXmoney, Simply Wall St, YCharts, Stockhouse, InvestorsHub, MarketBeat, Market Screener, Morningstar, Wallet Investor, and MarketWatch reported earlier on Second Sight Medical Products, Inc. (EYES), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Second Sight Medical Products, Inc. is a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision to blind individuals. The Company’s dedication is to developing new technologies to treat the broadest population of sight-impaired individuals. Second Sight is a recognized international leader in neuromodulation devices for blindness. Second Sight Medical Products has its U.S. headquarters in Los Angeles, California. Its European headquarters are in Lausanne, Switzerland. The Company lists on the NasdaqGS.

Second Sight (inspired by personal connections with a retinitis pigmentosa (RP) diagnosis) has researched, designed, and created the world’s first FDA and CE Mark approved device for providing artificial vision in people with late-stage RP. It is developing a cortical stimulation device that bypasses the diseased eye and has the potential to provide a new form of vision to individuals blinded because of a broad range of causes.

Second Sight has its Centers of Excellence – Argus Centers. To date, Argus II has been implanted in over 350 patients globally across greater than 25 exclusive regional centers. These include some of America’s most prestigious and highly regarded academic institutions. New centers are constantly added to provide total support of North America.

Recently, Second Sight Medical Products announced receipt of a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is intended to accelerate the integration of SLAM into next generation versions of Second Sight’s Orion® Visual Cortical Prosthesis System (Orion).

Second Sight and APL will use the NIH grant to capitalize on recent advances in computer vision, including object recognition, depth sensing and SLAM, to augment the existing capabilities of Orion. The aim is to give Orion users the ability to localize objects and navigate salient landmarks in unfamiliar surroundings in real time. APL will take the lead in developing the SLAM technology. Second Sight will be responsible for its integration and subsequent clinical deployment.

Second Sight Medical Products, Inc. (EYES), closed Friday's trading session at $0.74, off by 3.6207%, on 270,157 volume with 591 trades. The average volume for the last 3 months is 342,380 and the stock's 52-week low/high is $0.635100007/$1.76999998.

chart

Trucept, Inc. (TREP)

Stock News Now, Stock Pulse, PR Newswire, Infront Analytics, Business Insider, Investing Online, and Biz Journals reported earlier on Trucept, Inc. (TREP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trucept, Inc. is a foremost consulting and service provider to the Professional Employer Organization and Consumer Goods industries. By way of its subsidiaries, it provides professional employer organization staffing and business processing services to small and medium-size businesses in the United States. The Company previously went by the name Smart-Tek Solutions, Inc. It changed its name to Trucept, Inc. in January of 2013. Trucept is based in San Diego, California. The Company lists on the OTC Markets.

Trucept services allow customers to outsource human resources tasks. This includes payroll processing, workers' compensation insurance, health insurance, employee benefits, 401k investment services, personal financial management, and income tax consultation chiefly related to staffing comprising staff leasing, temporary staffing, and also co-employment.

In addition, Trucept provides healthcare staffing services. The Company’s services also relieve existing and potential customers of the burdens associated with personnel management and control.

Trucept announced in May 2019 the expansion of its Strategic Marketing and Technology products and services by appointing Fawad Nisar as Executive Vice President for its new wholly-owned subsidiary, Trucept Marketing, Inc. Trucept Marketing will assist marketing partners with a CBD (cannabidiol) line to wholesalers and distributors, with a processing and production capacity of 52kg of pure CBD oil per week.

Nisar brings valuable expertise within the Cannabis industry, particularly in product development, sales & marketing of CBD. CBD is the non-psychoactive ingredient of the cannabis plant. The passing of the 2018 Farm Bill removes hemp and its extracts as a controlled substance. This paves a path for hemp-derived CBD to reach consumers across the nation.

Nisar spent 13 years at Trellist Marketing & Technology, providing business consulting, brand and marketing strategy, and technology expertise to Fortune 500 enterprise clients in healthcare, pharmaceuticals, retail, manufacturing, and financial industries. Nisar has a Bachelor's and Master's degree in Chemical Engineering from Manhattan College.

Trucept, Inc. (TREP), closed Friday's trading session at $0.026, off by 20.00%, on 49,000 volume with 5 trades. The average volume for the last 3 months is 23,664 and the stock's 52-week low/high is $0.009999999/$0.195999994.

chart

alpha-En Corporation (ALPE)

Zacks, Stocksbeat, Invest Tribune, Otc.watch, Market Screener, PR Newswire, 4-Traders, Last10k, InvestorsHub, Wallet Investor, TradingView, and Simply Wall St reported earlier on alpha-En Corporation (ALPE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

alpha-En Corporation is an innovative clean technology company listed on the OTC Markets OTCQB. It focuses on enabling next generation battery technologies through developing and bringing to market pure, state of the art materials produced in an environmentally sustainable manner. The Company has developed a patent pending process for the production of lithium metal and associated products produced at room temperature. alpha-En is headquartered in Yonkers, New York.

The Company is enabling next generation energy storage. Its lithium metal is purer than what is presently available on the market. It is free of all base metals and common non-conductive impurities found in the existing commercial supply.

alpha-En produces its lithium employing a room temperature process (process conducted at 20°-30°C), which does not require or release noxious chemicals. The Company’s process allows for the flexible deposition and intercalation of lithium into custom substrates that streamlines the manufacturing of batteries of all sizes. alpha-En’s novel process is mercury and chlorine free. It eliminates the use and release of toxic chemicals and expensive containment costs. The Company’s electrodeposition method produces thin films of highly pure lithium on a host of substrates.

Strategic partners of alpha-En include Argonne National Laboratory and Princeton University. The Company’s first-rate Scientific Team includes a Nobel Prize winning Chemist.

Last month, alpha-En announced that it received a $1 million technology development grant from the New York State Energy Research and Development Authority (NYSERDA). This funding will help to pay for the considerable amount of research and development (R&D) required to bring disruptive battery technology from the laboratory to final commercialization.

NYSERDA administers many programs and initiatives via its Innovation portfolio to provide entrepreneurs and early-stage companies exclusive access to development partners, investors, as well as talent. On the whole, NYSERDA is deploying $800 million over 10 years as direct investments and commercialization support for early-stage ventures.

Mr. Jerome Feldman, Executive Chairman of alpha-En, said, "We are delighted and honored that NYSERDA has chosen our patented and proprietary technology to be worthy of its support. This is another milestone for our company in its mission to change the way energy is stored and utilized.”

alpha-En Corporation (ALPE), closed Friday's trading session at $0.60, up 33.3333%, on 200 volume with 2 trades. The average volume for the last 3 months is 4,695 and the stock's 52-week low/high is $0.159999996/$1.64999997.

chart

Summer Energy Holdings, Inc. (SUME)

StoxkEarnings, Zacks, All Stocks Today, Momentous News, Market Exclusive, Simply Wall St, Stockopedia, Wallet Investor, Capital Cube, Dividend Investor, Marketbeat, last10k, and InvestorsHub reported earlier on Summer Energy Holdings, Inc. (SUME), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Summer Energy Holdings, Inc., is the parent company of licensed retail electric providers (REPs) that are active in Texas, Massachusetts, New Hampshire, and (soon) Ohio. Summer Energy, LLC, is a wholly-owned subsidiary of Summer Energy Holdings, Inc. Summer Energy, LLC serves residential and commercial customers across Texas including Dallas/Fort Worth Metroplex, Houston and the Greater Houston area, Corpus Christi and surrounding cities. OTCQB-listed and founded in April of 2011, Summer Energy Holdings is based in Houston, Texas.

The Company has an experienced management team. Its Chief Executive Officer successfully built and sold a retail electric provider (Gexa Energy), developing the roadmap for Summer Energy Holdings. The Company was named 2017 Supplier of the Year by The Energy Professionals Association (TEPA). Furthermore, in 2018, it was selected for the third consecutive year as one of Houston’s Best and Brightest Companies to Work For. It was the only retail electric provider to make the list.

In essence, Summer Energy Holdings provides commercial and residential customers with reliable, cost effective power in certain states with deregulated power markets. The Company offers power price stability to customers versus their local utilities. Summer aggregates and forecasts demand across all of its customers, then acquires power to meet that forecasted demand from its wholesale power provider, EDF. In addition, Summer provides billing services in certain jurisdictions.

Each day, as its customers use power, Summer monitors and balances its power supply to meet its customers requirements. Furthermore, on a monthly basis it tracks and settles customer power use and bill its customers directly, or provides the information to the appropriate local utilities.

Summer’s customer base, measured by RCEs, has grown from approximately 20k at Year End 2013 to approximately 200k at Year End 2018. This represents 10x growth. Summer Energy Holdings has an asset and overhead light business model. The Company uses external brokers for new customer identification. This minimizes overhead costs.

The Company’s subsidiaries have signed a three year agreement with EDF Energy Services and EDF Trading North America (EDF) to provide them with wholesale power and other services. EDF is one of the largest players in the wholesale power market.

Summer Energy Holdings, Inc. (SUME), closed Friday's trading session at $1.85, up 22.5166%, on 1,980 volume with 3 trades. The average volume for the last 3 months is 263 and the stock's 52-week low/high is $1.35000002/$2.49.

chart

Dakota Territory Resource Corp. (DTRC)

InvestorsHub, Zacks, Market Screener, YCharts, TradingView, Stockhouse, Barchart, Simply Wall St, Uptick Newswire, Real Investment Advice, Innovative Marketing, OTC Markets Group, Ultimate Penny Stock, MarketWatch, The Street, Marketbeat, Dividend Investor, last19k, Wallet Investor, Corporate Information, and 4-Traders reported earlier on Dakota Territory Resource Corp. (DTRC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dakota Territory Resource Corp.’s emphasis is on the acquisition and responsible exploration and development of high caliber gold properties in the Black Hills of South Dakota. The Company maintains 100 percent ownership of three gold properties encompassing roughly 4,059 acres. These include the Blind Gold, City Creek, and Homestake Paleoplacer Properties. All of these properties are in the heart of the Homestake District. OTCQB-listed, Dakota Territory Resource is headquartered in Reno, Nevada.

The Company’s flagship property is the Blind Gold Property, which is a target for Tertiary-aged and Iron-formation gold mineralization. The Blind Gold Property is about four miles northwest and on structural trend with the historic Homestake Gold Mine.

The Homestake Gold Mine produced roughly 40 million ounces of gold through its 125-year production history. It is the largest iron-formation-hosted gold deposit in the world.

Dakota Territory’s plan is to continue its sampling program along trend of the zone of high grade gold mineralization identified by the first pass surface sampling program conducted on its 100 percent owned Blind Gold Property. The program identified a zone of high-grade gold mineralization in the Mississippian-age Pahasapa Limestone on the surface, with a peak gold assay value of 9.44 grams per tonne.

The Homestake Paleoplacer Property consists of 13 unpatented lode mining claims. These are situated one-mile north of the Homestake Open Cut. Dakota based the acquisition of its Black Hills property position on more than 44 years of combined mining and exploration experience in the Homestake District.

The Company’s City Creek Property is a target for Homestake iron-formation gold mineralization. City Creek consists of 21 unpatented lode mining claims. These are positioned one-mile northeast of the Homestake Open Cut and one-mile northwest of the City of Deadwood.

This week, Dakota Territory Resource announced the appointment of Mr. Lee Graber to the Company’s Strategic Advisory Committee. Mr. Graber has more than four decades of experience in the mining industry. This includes 23 years with Homestake Mining Company, one of the largest gold mining companies in the U.S. until it was acquired in 2002 by Barrick Gold Corporation.

As Homestake's Vice President responsible for corporate development, Mr. Graber initiated, managed, and closed manifold joint venture agreements, major acquisitions, and divestment transactions. After Homestake, Mr. Graber served as Managing Director, Mergers and Acquisitions, for Endeavour Financial Ltd.

Dakota Territory Resource Corp. (DTRC), closed Friday's trading session at $0.10, up 17.6471%, on 604 volume with 2 trades. The average volume for the last 3 months is 64,378 and the stock's 52-week low/high is $0.019999999/$0.191750004.

chart

RespireRx Pharmaceuticals, Inc. (RSPI)

NetworkNewsWire, Penny Stock Tweets, Infront Analytics, Stockflare, Barchart, InvestorsHub, Stockopedia, Penny Stock Hub, Wallet Investor, Simply Wall St, Marketbeat, YCharts, Street Insider, Marketwired, Stockhouse, Daily Marijuana Observer, last10k, Investors Hangout, GuruFocus, MarketWatch, Stockwatch, 4-Traders, and Real Investment Advice reported earlier on RespireRx Pharmaceuticals, Inc. (RSPI), and today we report on the Company, here at the QualityStocks Daily Newsletter.  

RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders and CNS indications, with a concentration on obstructive sleep apnea, attention deficit hyperactivity disorder (ADHD), spinal cord injury, other neurological conditions and drug-induced respiratory depression. RespireRx Pharmaceuticals has its corporate office in Glen Rock, New Jersey. The Company lists on the OTC Markets Group’s OTCQB.

RespireRx has filed over 400 patents in the U.S. and offshore that claim composition of matter, use, formulation, dosage, as well as mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, and also for improving memory and cognition, treating schizophrenia and other central nervous system (CNS) indications.    

  The Company’s pharmaceutical candidates in development are derived from two platforms. One platform is the class of compounds called cannabinoids. This includes, in particular, Dronabinol. Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. Dronabinol (D9-THC) is a generic, orally active cannabinoid. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA).

RespireRx Pharmaceuticals (under a license agreement with the University of Illinois) has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders. Two Phase 2 clinical trials have been completed. Both have demonstrated substantial reductions in sleep apnea produced by dronabinol. 

Dronabinol is Food and Drug Administration (FDA) approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinol®). It is a Schedule III drug available by prescription, with a low risk of addiction.

The other platform of medicines undergoing development by RespireRx is a class of proprietary compounds called ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain. Several ampakines, in oral and injectable form, are undergoing development by RespireRx for the treatment of an assortment of breathing disorders.

Earlier this month, RespireRx Pharmaceuticals announcd the promotion of Mr. James Sapirstein to Executive Vice Chairman of the Board of Directors effective December 28, 2018. Mr. Sapirstein has served as a member of the Board of Directors since 2014. He expands his role within RespireRx Pharmaceuticals to assist with business development and fundraising activities to advance the development of the Company’s pipeline of neuromodulators with an emphasis on sleep apnea and neurologic and psychiatric disorders.

Mr. Sapirstein is a highly-regarded pharmaceutical industry executive. He has more than 35 years of success in building companies and leading the commercial launch of almost two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. Mr. Sapirstein has worked at major pharmaceutical companies, Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly. He has also led commercial teams for biotechnology companies including Gilead Sciences and Serono Laboratories.

RespireRx Pharmaceuticals, Inc. (RSPI), closed Friday's trading session at $0.35, up 29.6296%, on 1,304 volume with 4 trades. The average volume for the last 3 months is 1,381 and the stock's 52-week low/high is $0.222000002/$1.10000002.

chart

Escalon Medical Corp. (ESMC)

Stock Twits, Dividend Investor, Zacks, Morningstar, Market Screener, Simply Wall St, Wallet Investor, OTC Picks, MarketWatch, last10k, GuruFocus, Capital Cube, Stockhouse, last10k, Equity Clock, Wall Street Resources, FeedBlitz, PennyToBuck, 4-Traders, InvestorsHub, and YCharts reported previously on Escalon Medical Corp. (ESMC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Escalon Medical Corp. specializes in the development, marketing, and distribution of ophthalmic diagnostic imaging and surgical products. It is working to grow its ophthalmic business through concentrating on its existing products, developing new products, utilizing strategic partnerships, and through acquisition.

Escalon Medical has its corporate headquarters in Wayne, Pennsylvania. The Company also has operations in Lake Success, New York; New Berlin, Wisconsin, and Stoneham, Massachusetts. Escalon Medical’s shares trade on the OTC Markets Group’s OTCQB.

Escalon Medical primarily markets to teaching institutions, hospitals, and eye surgery centers. The Company acquired Sonomed, Inc. in 2000. Since then, by way of acquisition, product divestitures, partnerships, and product development, it has grown and expanded its product offerings. Sonomed, Inc. and Escalon Medical Imaging are wholly-owned subsidiaries of Escalon Medical Corp.

Escalon Medical’s products include an assortment of ophthalmic ultrasound, digital imaging and photography, and image management systems. In addition, its products include surgical products, including intraocular gases, fiber optic light guides and sources, and other surgical vitreoretinal instruments.

All of the Company’s ophthalmic products are branded as Sonomed Escalon.  Furthermore, Sonomed Escalon maintains certification for compliance with ISO1385 Quality Management Systems for Medical Devices.

Sonomed Escalon provides ultrasound, digital photography, and image management systems. Sonomed Escalon Rx products include mydriatics/cyclopegics; diagnostic supplies; anesthetics/combo products; antibiotics, steroid combination; injectable dyes, surgical products, and office products.

Concerning tonometry, Sonomed Escalon has its “diatom IOP measuring device.” This involves measuring IOP through the eyelid on sclera with no corneal contact. It rapidly provides accurate IOP reading independent of corneal thickness. Additionally, it is ideal for cases where standard tonometry cannot be used. No anesthesia is required and there is no need to remove contact lenses, no need for sterilization, and no patient discomfort or anxiety.

Moreover, surgical solutions offered include vitreoretinal gases and devices. Its diagnostic solutions include AXIS image management; ophthalmic ultrasound; mobile vision analysis; adaptive refractor; perimetry; digital imaging, and tonometry.

Sonomed Escalon offers its Vu Pad pertaining to Ophthalmic Ultrasound. This is a new class of ophthalmic ultrasound versatility. Vu Pad is configurable with B-scan, A-scan, UBM or any combination.

Escalon Medical established in 1987. The Company sells its products to medical institutions by way of independent sales representatives, a network of distributors, and internal sales employees.

Escalon Medical Corp. (ESMC), closed Friday's trading session at $0.1194, up 45.4324%, on 400 volume with 2 trades. The average volume for the last 3 months is 49,730 and the stock's 52-week low/high is $0.082000002/$0.248999997.

chart

International Stem Cell Corp. (ISCO)

Tip.us, MissionIR, Serious Traders, Tiny Gems, Market Screener, StockInvest, Marketbeat, GuruFocus, Equity Clock, Research Gate, Canadian Insider, StocksToBuyNow, Zacks and Morningstar reported earlier on International Stem Cell Corp. (ISCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

International Stem Cell Corp. is a clinical stage biotechnology company headquartered in Carlsbad, California. It is developing stem cell-based therapies and biomedical products. The Company’s focus is on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. International Stem Cell has a research facility in Oceanside, California.

The Company’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. They offer the potential to create the first true stem cell bank, UniStemCell™.

The UniStemCell™ bank is the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use. The human leukocyte antigen (HLA) system represents antigens vital for transplantation.

  International Stem Cell scientists have created the first parthenogenetic, homozygous stem cell line. The Company produces and markets specialized cells and growth media for therapeutic research around the world through its subsidiary Lifeline Cell Technology and stem cell-based skin care products through its subsidiary Lifeline Skin Care.

This past November, International Stem Cell announced positive 12-month results of the first cohort and six-month interim results of the second cohort of its presently-ongoing, single-arm, open-label phase 1 clinical study (NCT02452723) evaluating the safety and tolerability of its lead candidate, ISC-hpNSC®, a cellular therapeutic comprising human parthenogenetic neural stem cells, for the treatment of Parkinson’s disease (PD).

Six of the 12 patients in the clinical trial completed one year of follow-up observations. One patient in the low dose cohort has now been followed for 2 years. There have been no safety signals or serious adverse effects seen to date as related to the transplanted ISC-hpNSC® cells.

The evaluation is based on greater than 12 months of safety data from the first cohort (low dose), and 6 months of data from the second cohort (mid dose). Each cohort consists of 4 patients. Dosing of patients in Cohort 3, which is receiving the highest dose, is ongoing.

International Stem Cell Corp. (ISCO), closed Friday's trading session at $0.73245, up 28.50%, on 6,622 volume with 17 trades. The average volume for the last 3 months is 6,653 and the stock's 52-week low/high is $0.351200014/$1.89999997.

chart

Mobiquity Technologies, Inc. (MOBQ)

PennyStocks24, PennyPickAlerts, Penny Stock Circle, 1-2-3 Stock Alerts, StockRockandRoll, PennyStockLocks.com, ResearchOTC, Stock Commander, SmallCapVoice, and StockMister reported earlier on Mobiquity Technologies, Inc. (MOBQ), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Mobiquity Technologies, Inc. operates a national location-based mobile advertising network. This network has developed a consumer-focused proximity network. Mobiquity Networks is a wholly-owned subsidiary of Mobiquity Technologies. Mobiquity Networks is the largest network of retail mall-based mobile advertising beacons in America. Mobiquity Networks is a next generation mobile location data intelligence and marketing company. Mobiquity Technologies is based in Garden City, New York.

Mobiquity Networks provides precise, unique, at-scale location based data and insights on consumers' real world behavior and trends. This is for use in marketing and research.

Mobiquity Technologies has exclusive agreements in hundreds of premier U.S. shopping malls. Its integrated group of unique location-based mobile advertising technologies enables retail and entertainment brands to execute personalized and contextually relevant experiences. This boosts brand awareness and incremental revenue.

Mobiquity Technologies is continuing to work to expand its location-based mobile advertising solutions to create "smart malls" in retail destinations throughout the U.S. employing Bluetooth-enabled iBeacon technology. By way of its subsidiaries, the Company provides brand marketing, advanced integrated marketing platforms, mobile marketing, social networks, Website development, and digital media solutions. It provides brand analysis and development, Website analysis and development, database analysis and building, and integrated marketing campaigns using direct mail, email marketing, mobile marketing, promotional products, and other mediums.

Furthermore, Mobiquity Technologies provides a proprietary Web development platform and delivers a content management system that puts content control back into the clients’ hands. The Company also provides hyper-local mobile marketing solutions. This includes a location-based marketing tool, which delivers digital content to Bluetooth or Wi-Fi enabled devices.

In June 2017, Mobiquity Networks announced the launch of the Passage Platform. This is its newly enhanced mobile device location platform. The new Passage Platform provides a significant leap ahead in the way marketers will be able to optimize active campaigns by measuring visits in real time.

This platform provides contextual and actionable insights. It enables marketers to more deeply engage with their most valuable consumers.

The Passage Platform provides a direct connection and deep understanding of consumers’ visitation behavior and engagement. The next generation business intelligence will enable store owners to enhance the in-store experiences and marketers their advertising strategy to increase visits.

In July of this year, Mobiquity Networks announced a new member to its team, Mr. Yuan Zhao. Mr. Zhao has a first-rate background in computer and data sciences. He joins the Mobiquity Networks development team as lead data scientist.

Mr. Zhao’s main goal will be enhancing Mobiquity’s Passage Platform with analytics and machine learning applications to further enrich data for customers. He comes to the Company from the IBM Watson Research Center, where he specialized in Geo-spatial Data and Audience Insights.

Mobiquity Technologies, Inc. (MOBQ), closed Friday's trading session at $0.14, up 16.6667%, on 151,593 volume with 31 trades. The average volume for the last 3 months is 165,987 and the stock's 52-week low/high is $0.07/$0.239999994.

chart

The QualityStocks Company Corner

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram stock has bounced back almost 20% from its 52-week low over the past few weeks. Let’s analyze whether Organigram Holdings (TSX:OGI) (NASDAQ:OGI) has reached the bottom or not. There is absolutely no doubt that the marijuana industry has gone through a pretty tough period over the course of the past months, and many of the stocks have collapsed from their peaks this year. However, certain companies continue to do well despite a slowdown in the industry.

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Friday's trading session at $3.41, up 2.4024%, on 916,571 volume with 3,067 trades. The average volume for the last 3 months is 3,139,581 and the stock's 52-week low/high is $2.71000003/$8.43999958.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) is pursuing multiple channel marketing strategies to achieve a national profile. PLUS has also launched its first commercial, digitally available directly to consumers (http://cnw.fm/0yY5z). Also today, CannabisNewsWire released a report on the company detailing how PLPRF recently released its infused-gummies product line, which contains the two best-selling cannabis products in California, in Nevada (http://cnw.fm/Hp6zE ). To view the full article, visit http://cnw.fm/lO7kO .

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Friday's trading session at $1.70, up 6.1836%, on 75,891 volume with 120 trades. The average volume for the last 3 months is 39,351 and the stock's 52-week low/high is $1.43459999/$6.00810003.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF)prides itself on its dedication to producing premium, certified-organic cannabis. An article discussing the company reads, “Growing certified-organic cannabis doesn’t just benefit consumers. The process is also better for the community, the soil and the environment. To view the full article, visit http://cnw.fm/F7lXA.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Friday's trading session at $0.8565, up 12.7122%, on 1,774,353 volume with 1,265 trades. The average volume for the last 3 months is 2,700,787 and the stock's 52-week low/high is $0.685999989/$4.38000011.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced that results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published in the peer-reviewed medical journal Advances in Therapy. (http://cnw.fm/s1Ue7). To view the full article, visit http://cnw.fm/Wni58. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. When suffering from chronic pain, medical marijuana can help you manage the pain. And since you need to use medical marijuana several times a day, your body may become tolerant of the medicine to the point where your pain does not abate ultimately and leaves you needing more to function normally.

The recent climb in the stock price of Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)looks to be the harbinger of a bright future for the innovative global developer of drug-delivery platforms. After the FDA announced it had authorized the marketing of products through the modified-risk, tobacco-product (MRTP) pathway, LXRP stock jumped 24 percent, up to $0.72 from $0.58 on the OTC Markets.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hmep-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Friday's trading session at $0.582575, up 5.9227%, on 33,881 volume with 39 trades. The average volume for the last 3 months is 171,387 and the stock's 52-week low/high is $0.399800002/$1.70000004.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood, Inc. (OTCQB: NGTF), the start-up ice cream company addressing America’s $50 billion-dollar nighttime snacking problem, announced today that CEO Sean Folkson conducted an interview with Wall Street Reporter in advance of the November 14, 2019 presentation at the Super Stock Live Conference.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Friday's trading session at $0.2729, up 1.0741%, on 98,480 volume with 32 trades. The average volume for the last 3 months is 147,763 and the stock's 52-week low/high is $0.160099998/$0.920000016.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America (OTCQB: MCOA) was featured today in the 420 with CNW by CannabisNewsWire. Cannabidiol (CBD) is, without a doubt, one of the most potent and versatile medicines we have come across in recent times. It has more uses than most pharmaceuticals, and it is easier on the body too. The cannabis extract has proven effective against a variety of medical conditions ranging from chronic pain, and high blood pressure to seizures in epileptic children.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Friday's trading session at $0.19, up 1.8767%, on 110,909 volume with 115 trades. The average volume for the last 3 months is 665,067 and the stock's 52-week low/high is $0.023/$2.10599994.

Recent News

chart

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy Inc. (TSXV:PQE; OTC:PQEFF; FSE: PQCF), a fully integrated surface oil sands mining oil company with proprietary technology‎, announces that, subject to TSX Venture Exchange (“TSXV”) approval, it intends to amend two 12 month unsecured convertible debentures, originally issued in October 2018, for an aggregate ‎of US$500,000 principal amount bearing interest at a rate of 10% per annum and payable on maturity.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Friday's trading session at $0.178, up 7.9442%, on 507,408 volume with 81 trades. The average volume for the last 3 months is 380,376 and the stock's 52-week low/high is $0.112099997/$0.819999992.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Thursday announced its filing of a preliminary information statement with respect to a proposed reverse stock split of its common stock at a ratio of between 1 for 100 and 1-for-1,000. To view the full press release, visit http://nnw.fm/whED3.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Steven C. Levin, M.D., Scientific Advisory Board Member
Dr. Steven C. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology. Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. Additionally, Dr. Levin has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center. Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.

Peter Novak, M.D., Ph.D., Scientific Advisory Board Member
Dr. Peter Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

Geoffrey Abrams, M.D., Scientific Advisory Board Member
Dr. Geoffrey Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for Stanford’s varsity athletes. He specializes in orthopedic sports medicine and arthroscopy of the shoulder, knee and elbow as well as upper extremity joint replacement surgery. Dr. Abrams is a member of the American Academy of Orthopedic Surgeons (AAOS) and the American Orthopedic Society for Sports Medicine (AOSSM), among others, and currently serves as assistant team physician for the NFL’s San Francisco 49ers as well as head team physician for a number of Stanford University varsity athletic teams. He is actively involved in research focusing on the role of inflammatory mediators, and microRNA in particular, on cartilage and tendon damage. Dr. Abrams received his undergraduate degree from Stanford University and his doctorate of medicine from the University of California – San Diego. He completed his residency in orthopedic surgery at Stanford University and went on to receive additional training in Orthopedic Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Abrams has authored or co-authored over 60 peer-reviewed scientific articles, over 20 book chapters, has presented original research at numerous national and international scientific meetings, and serves as a reviewer for numerous sports medicine scientific journals.

Dr. William Li, Scientific Advisory Board Member
Dr. William Li is CEO and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies. Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost-effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.

Mykol Larvie, Scientific Advisory Board Member
Recipient of three Harvard Medical Student Teaching awards in Principal Clinic Experience, Mykol Larvie is currently a radiologist in the Cleveland Clinic’s Divisions of Nuclear Medicine and Neuroradiology as well as the director of Functional and Molecular Neuroimaging. With a completed internship in the Department of Medicine as well residency in the Department of Radiology and fellowship in the Division of Neuroradiology at the Massachusetts General Hospital, Dr. Larvie specializes in PET examinations of the brain performed typically for the evaluation of neurodegenerative disease, seizure and tumor. He delivers didactic lectures and case conferences to residents and fellows six times per year and serves as a mentor and advisor to medical students, residents and fellows.

Nathan L. Guerette, Scientific Advisory Board Member
Nathan L. Guerette is the director and president of the Female Pelvic Medicine Institute of Virginia; an associate clinical professor in the division of Urogynecology and Pelvic Reconstructive Surgery at the Medical College of Virginia; a full clinical professor in Urogynecology and Pelvic Reconstructive Surgery at the Riverside Regional Medical Center; and the Robotic Surgery director at the Chippenham and Johnston Willis Medical Center. With a completed fellowship in urogynecology and pelvic reconstructive surgery at the Cleveland Clinic Foundation, Dr. Guerette has won seven awards in the medical and humanitarian departments. He has made nine media appearances, some of which were on PBS and NBC News. He has three board certifications and has ran a surgical mission trip to Trujillo, Peru, through Bon Secours.

Dr. Ashling O’Connor, Scientific Advisory Board Member
Currently a surgeon at the Comprehensive Breast Health Center of the Lahey Medical Center, Dr. O’Connor has won seven awards in the surgical department. She has completed a surgical internship at the Mater Misericordiae Hospital in Dublin as well as a breast surgery fellowship at the University of Massachusetts Interdisciplinary Breast Fellowship. She mentors medical students and surgical residents both in the operating room and in a clinical setting and enjoys biking and triathlons as well as trail and marathon running. She is certified in the Hidden Scar technique in breast surgery as well as in the advanced cardiac life support and is a member of the Protocol Review Committee Umass Memorial Medical Center, the New England Surgical Society and the American College of Surgeons.

Samir Awad, Scientific Advisory Board Member
Samir Awad has worked for the Department of Veterans Affairs since 2000. He has served as the operative care line associate executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad’s areas of specialty include liver, pancreas, and acute care surgery, as well as minimally invasive surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine. Dr. Awad has authored more than 100 peer-reviewed and invited publications and is the recipient of numerous awards for surgical and research achievements. Dr. Awad is certified by the American Board of Surgery and Surgical Critical Care.

Endonovo Therapeutics Inc. (ENDV), closed Friday's trading session at $0.0065, up 8.5142%, on 10,196,136 volume with 94 trades. The average volume for the last 3 months is 66,686,641 and the stock's 52-week low/high is $0.0035/$0.043999999.

Recent News

chart

B2Digital Inc. (OTC: BTDG)

The QualityStocks Daily Newsletter would like to spotlight B2Digital Inc. (BTDG).

B2Digital (OTC: BTDG) is now fully reporting after its recent filing of a Form 8-A Registration Statement with the U.S. Securities and Exchange Commission (“SEC”). To view the full article, visit http://nnw.fm/Kqtr6.

B2Digital Inc. (OTC: BTDG) is applying its extensive background in entertainment, television, video and technology to become a full-service live event sports company. Capitalizing on its strong management team, industry relationship, and hands-on experience in the industry, B2Digital is developing and acquiring Mixed Martial Arts (MMA) and sports-related companies to build an integrated premier development league initially for the billion-dollar MMA marketplace.

B2Digital’s management team boasts over 30 years of combined global experience developing more than 20 companies within the sports, television, entertainment, digital distribution and banking transaction industries.

Since its restructuring in 2017, the company is now forging ahead with company chairman and CEO Greg P. Bell at the helm. His expertise, relationships and experience bring a background of more than 40,000 successful live events throughout his career. Under his guidance, B2Digital will create and develop the “Development League” champions that will move on to the MMA major leagues from within the B2 Fighting Series.

In preparation, B2Digital has produced and applied the systems and technologies required to support and maintain infrastructural operations of the company, including: social media marketing, event management, digital ticketing sales, digital video distribution, digital marketing, PPV, fighter management, merchandise sales, brand management and financial control systems. The company has also launched its B2 Social Media Network as the digital distribution system for the B2 Fighting Series.

As part of its growth strategy, B2Digital intends to continue to develop and acquire assets that meet its business model with the goal of becoming a premier vertically integrated live event sports company. In 2017, B2Digital started operating B2 Fighting Series, live MMA events; each year, the top fighters are invited to the live annual B2 Fighting Series National Championship.

Assets

B2Digital owns all rights for TV, internet, social media, media, merchandising and trademarks and branding for the B2Digital companies. The company has deployed its B2 Social Media Network digital distribution network for the B2 Fighting Series and has developed and deployed the systems and technologies for the operation of social media marketing, event engagement, digital ticketing sales, digital video distribution, digital marketing, PPV, fighter management, merchandise sales, brand management and financial control systems.

Fight Groups (holdings)

  • HRMMA
  • Colosseum Combat
  • United Combat League
  • Pinnacle Combat
  • Bluegrass MMA

B2 Social Media Network (B2SN)

The B2 Social Media Network (B2SN) provides the connection between the B2Digital live events and the consumer audience by:

  • Providing social interaction between consumers regarding B2Digital Properties and current relevant topics to the live events audience
  • Offering “FTV” free-to-view live and on-demand TV style broadcasts globally of B2 Digital live events
  • Promoting upcoming live events
  • Selling tickets to B2 live events electronically
  • Promoting the fighters, athletes and participants in the B2Digital live events

Download Report

Leadership

Chairman and CEO Greg P. Bell
Greg P. Bell is one of the early pioneers and entrepreneurs in entertainment and digital media and has been working in the field for over 30 years. He was involved in the early creation of the technologies and algorithms that allowed analog media to be transformed into digital bits and compressed data streams and created specific business enterprises that capitalized on the creation of digital transmissions at Scientific Atlanta, Compressions Labs, VCON International and Qwest. Bell was one of the initial vice presidents of business development at Qwest Communications where he developed Qwest’s digital media company, Slingshot Networks. He then ran all operations of Slingshot, reporting to the board of directors, which managed and operated three full time studios including the creation of the broadcast studio in Staples Center, TV and news productions, live events at the Staples Center, distribution of a national television show distributed by Warner Brothers TV Distribution, online television productions and web distribution for the NFL, AFL, NBA, NHL, Boxing, Democratic Convention and live music events.

Upon leaving Slingshot in 2000, Bell founded B3 Development Group, a firm specializing in developing emerging market entertainment and media companies. Bell’s B3 Development Group founded B2 Networks in 2001 which quickly became the defacto standard for watching live PPV sporting events online. B2’s proprietary online system broadcasts live professional and collegiate sporting events online to a global audience, broadcasting over 1,000 live games per month. Bell developed and implemented a merger with B2 Networks and the America ONE Television Network where he became CEO of the combined companies. Under Bell’s direction the company, now called ONE Media Corp., launched the new ONE World Sports TV Network in North America on cable and satellite, with a pure digital end-to-end distribution system, along with continuing the company’s growth in the online distribution of sports and entertainment.

After leaving as CEO of ONE Media Corp., he currently sits as chairman of B3 Development Group, which specializes in developing and fast-tracking emerging entertainment, transaction technology and media distribution companies. Bell continues to expand his holdings and currently has business holdings in ONE Media Corp; B3 Development Gaming Group which under contract with Caymanas Park Race Track, owned by the country of Jamaica, developed Jamaica’s first all-digital state of the art pari-mutuel live sports gaming system for mobile devices and currently is operating under the brand CaymanasToGO for the Caribbean Consumers and is licensed for deployment in the USA to USA-based consumers. The B3 Gaming Group mobile device wagering system and technology allows consumers globally to watch and wager on live horse races and sporting events being held in the UK, USA, Canada and the Caribbean; B3 Gaming Services Group, a premier transaction and customer service group that offers management services to the Gaming industry in the Caribbean, B3 Networks, a premier state of the art digital broadcasting company that developed the B3 television satellite replacement technology which allows TV networks to broadcast globally on the public internet instead of satellites in broadcast quality HD & SD television. B3 Networks has deployed, and services, the B3 technology to broadcast high definition TV signals globally to cable head ends, smart phones and internet connected devices for the Jamaica Education Television Network, the Caymanas Race Track and other mobile applications globally.

Bell has worked at the top technology development companies that developed the digital technologies, which are in use today at Scientific Atlanta, Compression Labs, VCON and Qwest. He also has managed and been directly involved with over 55,000 live events in his 30-year career. He has worked with a diverse group of clients in the entertainment, sports and technology communities including the NFL, NBA, NHL, AHL, NLL, ECHL, IFL, USHL, SPHL, NCAA, NAIA, MISL, AFL, AOL, FOX, UFC, NAAFS, Bellator, WEF, the Staples Center, the Orleans Arena, Oscar De La Hoya, Barbra Streisand, and top entertainment venues, acts and actors. His clients and companies have capitalized on Bell’s knowledge of the world of entertainment, live events, sports, digital television and digital online transaction and distribution systems.

B2Digital Inc. (BTDG), closed Friday's trading session at $0.0058, up 1.7544%, on 100,000 volume with 1 trade. The average volume for the last 3 months is 303,249 and the stock's 52-week low/high is $0.0023/$0.039999999.

Recent News

chart

Xalles Holdings Inc. (OTC: XALL)

The QualityStocks Daily Newsletter would like to spotlight Xalles Holdings Inc. (OTC: XALL).

Fintech holding company Xalles Holdings (OTC: XALL)is concentrating on the payment industry and financial technology. To view the full article, visit http://ccw.fm/4zV1v.

Xalles Holdings Inc. (OTC: XALL) is a fintech holding company leveraging blockchain and other technologies for e-commerce, payments, financial reconciliation, and payment auditing solutions. The company actively seeks acquisition targets with strong management teams and business models, large total attainable markets, and lucrative exit opportunities in which to invest and accelerate growth.

Operations

The common element to all acquired entities and projects is a business model that involves setting up a payment or financial transaction “toll gate,” thereby creating a recurring revenue stream.

Xalles’ business plan focuses on consumer, business and government-oriented payment and financial reconciliation transactions. Combining the blockchain decentralized financial ledger platform with the company’s existing X2X transaction reconciliation system design, Xalles is building technology that supports payment audits, exchanges, and new business models and opportunities worldwide. Xalles will launch new services card and mobile payment and rewards systems, and will expand the technology offerings for referral marketing and e-commerce engines.

Subsidiaries
All current subsidiaries are wholly owned

  • Xalles Holdings
    Raise capital for fintech accelerator program acquisitions, provide management, administrative, finance and marketing support to all subsidiary companies
  • Xalles Capital
    Management support of investment consortiums, direct investment into funds or projects, and management of investments
  • Xalles Limited
    Design and market new X2X solutions; acquire U.S Government transportation post-payment audit business through GSA schedule and expand to non-transportation payment auditing
  • Xalles Technology
    Technical development of the X2X blockchain systems
  • Xalles Financial Services
    Consumer and small business financial service offerings
  • Co-Owners Rewards
    Stock-based rewards system for payments cards and financial services
  • Amazing Living Enterprises
    Affiliate program and e-commerce platform for enhancing financial lives
  • Global Savings Network
    Not-for-profit fundraising system with consumer discounts at local merchants

X2X Solutions

Xalles provides payment and financial transaction management solutions through the company’s proprietary blockchain-based X2X technology. The X2X solution includes the Investment and Financing System (IFS), which supports complex investment structures, assists international investment consortia, and provides links to Xalles’ Financial Transaction Reconciliation (FTR) solution. FTR supports complex financial ecosystems, making it easier for parties to exchange products, services, grants and government incentives, and assists “Exchange Managers” with liquidity and auditability. X2X also supports the Xalles pre- and post-payment auditing services.

Advancements in 2019

  • Co-Owners Rewards subsidiary is working to launch a general purpose reloadable prepaid payment card with a stock rewards program.
  • Previously announced LYC Mortgage acquisition will create a structure that will dramatically increase revenues in 2020 with new mortgage business portfolios.
  • Xalles Financial Services expects to launch the Cryptocurrency Trading Engine and acquire multiple cryptocurrency asset portfolios to drive increases in value through the trading engine.

“The structure and growth plan for the company contains a balance of diversity and synergy so that we can effectively use limited resources to obtain the best results. We will see the culmination of the fundraising efforts, acquisitions and organic growth in the second half of 2019 put us on the path to tremendous growth in 2020.”

– Xalles CEO Thomas Nash (http://nnw.fm/rU6iT)

Xalles Holdings Inc. (OTC: XALL), closed Friday's trading session at $0.0045, up 2.2727%, on 794,304 volume with 18 trades. The average volume for the last 3 months is 2,168,896 and the stock's 52-week low/high is $0.0013/$0.021029999.

Recent News

chart

CloudCommerce (OTCQB: CLWD)

The QualityStocks Daily Newsletter would like to spotlight CloudCommerce (OTCQB: CLWD).

CloudCommerce, Inc. (CLWD), a leading provider of digital marketing solutions, today commented that it is benefiting from the dramatic transition in the US from traditional advertising to digital advertising.

CloudCommerce (OTCQB: CLWD) is a leading provider of audience-driven business intelligence and marketing solutions. Together with its wholly owned subsidiaries, CloudCommerce delivers invaluable end-to-end business intelligence and marketing solutions through a range of services and capabilities.

Flagship Solution

SWARM is an end-to-end solution that applies advanced data science, behavioral science, artificial intelligence and market research techniques to deliver powerful audience-driven business intelligence that converts opportunities into business success.

Through marketing, brand perception, customer-relationship management, human-resources management and operational logistics applications, CloudCommerce’s SWARM solution helps businesses determine who to talk to, what to say and how to motivate targeted audiences to take meaningful action.

The Market

Marketers have largely taken a blanket approach to communication. The same messages are often sent across an entire customer audience with little regard for how different groups of people communicate, build communities and develop their purchasing habits. When marketers do segment audiences, they use objective selection criteria such as income, geography, education or purchase history to deduce attitudes or intentions.

However, research shows that motivations and feelings are much more accurate at predicting behavior. The challenge for businesses is that these factors are also the hardest to gather from audience data. CloudCommerce provides that audience-intelligent data through SWARM, its proprietary behavioral-science approach to audience creation and communication. Through SWARM, CloudCommerce helps marketers identify consumer motivations and triggers in order to effectively predict and influence actions. When companies influence action, they can change opinions, gather support, motivate purchases and inspire change.

In a fast-developing global business intelligence market estimated to grow from $16.3 billion in 2016 to $34.3 billion by 2022, CloudCommerce stands apart as an innovator and true partner, able to deliver data-driven intelligence and solutions that enable its customers to strengthen their brands, deliver their messages and reach their goals.

SWARM Products

THE SWARM—Intelligent Audience Building
The core of the CloudCommerce solution – and what separates CloudCommerce from other audience data companies – is the company’s unique approach to audience building. The concept of “personas” has been around for decades, but CloudCommerce takes that concept to the next level. The SWARM was developed to identify not only who to talk to but also what to say in order to motivate target audiences to take meaningful action. Using CloudCommerce’s proprietary clustering and behavioral analysis techniques, businesses can identify target audiences and deliver messages that are more focused and efficient. CloudCommerce not only helps its client partners find the right people to talk to but also identifies the most powerful message to send.

BUZZ—Behavior-Based Market Research
Market research is evolving. Research techniques developed and used today are more sophisticated and backed by strong data science. Despite these changes, many traditional research firms have failed to innovate: small sample sizes, survey design bias, improper weighting and gut-intuition sampling are just some of the issues that plague the market-research industry. Through BUZZ, CloudCommerce has automated the market research process to provide a level of statistical depth beyond what traditional firms can offer. BUZZ offers businesses the ability to put their finger on the pulse of the marketplace in the moment. Using a wide range of internal and external data sources such as customer data, social media activity, and micro and macro trends, BUZZ deduces attitudes, emotions and opinions.

HIVE—Redefined Geographic Targeting
Conventional geographic audience targeting is outdated. Arbitrary units of location such as counties, cities, DMAs and regions were created centuries ago based on land-rights ownership. Their use in understanding people’s behavior, purchase habits and underlying values is minimal. CloudCommerce has found a much more powerful, efficient and effective way of targeting by clustering people into granular geographic tribes called HIVES. HIVES are defined by attributes such as common language (e.g., colloquialisms), shared experience and narratives (e.g., climate, history), and concentrated demography and biology (e.g., ethnicity, age). Based on the needs of its clients, CloudCommerce can completely redraw the geographic lines based on various Hive selection criteria. Using this exclusive HIVE approach, CloudCommerce clients experience more efficient and effective marketing, make more intelligent business decisions and enjoy more growth.

HONEY—Advanced Reporting and Visualization
Advanced-audience, data-analysis technologies are useless if they don’t produce simple, powerful and actionable business intelligence. HONEY comes with user-friendly reporting and visualization tools to organize and explain all of the advance-data science into a simple-to-understand format for decision makers. HONEY combines the intelligence of client CRM data with third-party consumer data and targeted market research to create a powerful foundation for any audience-intelligence solution.

Subsidiaries

Data Propria
Data Propria delivers the highest Return on Investment (“ROI”) for their customers’ digital marketing campaigns, by utilizing sophisticated data science to identify the correct universes to target relevant audiences. Their ability to understand and translate data drives every decision they make. By listening to and analyzing their customers’ data they are able to make informed decisions that positively impact their customers’ business. Data Propria leverages industry-best tools to aggregate and visualize data across multiple sources, and then their data and behavioral scientists segment and model that data to be deployed in targeted marketing campaigns. They have data analytics expertise in retail, wholesale, distribution, logistics, manufacturing, political, and several other industries.

Parscale Digital
Parscale Digital helps their customers get their message out, educate their market and tell their story. They do so creatively and effectively by deploying powerful call-to-action digital campaigns with national reach and boosting exposure and validation with coordinated advertising in print media. Parscale Digital’s fully-developed marketing plans are founded on sound research methodologies, brand audits and exploration of the competitive landscape. Whether their customer is a challenger brand, a political candidate, or a well-known household name, Parscale Digital’s strategists are skilled at leveraging data and creating campaigns that move people to make decisions.

Giles Design Bureau
Giles Design Bureau approaches branding from a “big picture” perspective, establishing a strong identity and then building on that to develop a comprehensive branding program that tells the customer’s story, and articulates what sets the customer apart from their competitors and establishes the customer in their market.

WebTegrity
WebTegrity develops commerce-focused, user-friendly digital websites and apps that elevate their customer’s marketing position and draw consumers to their products and services. Their platform-agnostic approach allows WebTegrity to architect and build solutions that are the best fit for each customer. Once the digital properties are built, their experts will help manage and protect the website or app and provide the expertise needed to scale the infrastructure needed as the customer’s business grows.

Leadership

Andrew Van Noy, CEO & Chairman of CloudCommerce Board of Directors
Andrew Van Noy has been a director of CloudCommerce since November 2012, president of the company since April 2012, and the CEO of the company since August 2012. He also served as executive vice president of CloudCommerce from November 2011 to April 2012 and vice president of Sales and Marketing of the company from May 2011 to November 2011. From January 2009 to April 2011, Van Noy served as the vice president of Sales and Marketing for PageTransformer, which provided web and software development for iPad, iPhone and Android devices. Van Noy came to CloudCommerce with experience in digital marketing, private equity and investment banking. During his years at the company, Van Noy led the efforts to rebrand and restructure the business and presided over the acquisition of a number of companies. Van Noy graduated from BYU with a Bachelor of Science degree.

Gregory Boden, CFO and Board of Directors
Gregory Boden became a director at CloudCommerce in November 2011 and in February 2013 was named corporate secretary. In April 2012, Boden was also appointed CFO. In addition, Boden is the managing partner of a private equity company. Prior to joining the CloudCommerce team, Boden managed the franchise accounting and cash application departments of Select Staffing, a nationwide staffing company and was an accountant at KPMG LLP. Boden earned his master of accountancy degree from the University of Denver.

Brad Parscale, Board of Directors
Brad Parscale creates web-marketing strategies and oversees all technical and functional aspects of these strategies. Originally from Kansas, Parscale spent five years in California before moving to San Antonio in 2004 to establish Parscale Media, a successful web-marketing firm. His 2011 partnership with Jill Giles formed Giles-Parscale Inc. In 2016, Parscale was named digital director for the Donald J. Trump presidential campaign.

Zachary Bartlett, VP of Corporate Development and Board of Directors
Zachary Bartlett has been a director of the company since July 2012 and was appointed vice president of Corporate Development in January 2018. Bartlett has also served as vice president of Communications and an independent contractor assisting with project management matters. Prior to joining CloudCommerce, Bartlett was the creative director at Crowbar Studios Inc., a graphic design and web development firm he founded in 2008. From 2004 to 2008, he held the position of art and brand consultant at Demon International, a snowboard accessories company. Bartlett earned his bachelor of fine arts degree in graphic design from Brigham Young University.

CloudCommerce (OTCQB: CLWD), closed Friday's trading session at $0.00288, up 6.6667%, on 1,862,750 volume with 12 trades. The average volume for the last 3 months is 1,211,091 and the stock's 52-week low/high is $0.0026/$0.0228.

Recent News

chart

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF)

The QualityStocks Daily Newsletter would like to spotlight Wonderfilm Media Corporation (OTC: WDRFF).

Wonderfilm Media (TSX.V: WNDR) (OTCQB: WDRFF) is a producer of high-quality feature films and episodic television with international appeal. An article discussing the company reads, “Earlier in October, Wonderfilm appointed PCG Advisory Inc., a leading investor-relations and digital-strategies firm, to serve as an advisor for its investor-relations and strategic communications. To view the full article, visit http://nnw.fm/0Cdpy.

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF) main business is the worldwide production of high-quality feature films and episodic television. The Wonder?lm team includes Hollywood veterans who have packaged, produced and delivered several profitable recent films, including “BlacKkKlansman,” “Get Out” and “The Hurt Locker.” Having these individuals on the Wonderfilm team demonstrates the company’s proven access to Academy Award-quality films and upside.

Wonder?lm maintains a continuing $58 million annual production slate to meet the constant and growing need for content worldwide. The company’s risk-averse production process results in predictable and consistent revenue streams.

Soaring demand for content from streaming providers is fueling industry growth. The global media and entertainment market is expected to grow from $1.9 trillion in 2017 to $2.4 trillion in 2022, a five-year CAGR of 4.4%.

The company recently formed Wonderfilm Global, an international film and television sales and distribution joint venture that is expected to generate significant incremental revenue.

Wonderfilm has strong relationships throughout the entertainment industry, which enables cost-effective production budgets and in-demand content creation.

Management Team with Proven Track Records

Kirk Shaw: Over 240 movies and seven television series to his credit. Headed up Canada’s largest independent film and television production company, attaining $100 million revenue two years straight with 8% EBITDA.

Dan Grodnik: Founded Mass Hysteria Entertainment, a publicly traded company, and became its chairman/CEO. Produced over 50 feature films, including “Bobby,” the 2006 Robert Kennedy biographic film.

Shaun Redick & Yvette Yates: $300 million+ USD total production budgets to date with a combined 175 award wins/355 nominations, including 10 Oscar nominations. In 2017 and 2018, they produced two of the most successful Hollywood films of those years: “Get Out” ($255 million USD gross revenue) and “BlacKkKlansman” ($100 million USD gross revenue). Scheduled to produce two to three films per year for Wonderfilm, with the first release slated for October 2020. Committed to the 4% challenge to give more women and women of color the opportunity to direct.

Jeff Bowler: 2017 Emmy Award-winning producer. Vice president of acquisitions and production for The Exchange, one of the top film sales and finance companies in the world. Bowler is the executive for Wonderfilm Global distribution.

Bret Saxon: Through his company, TMP Inc., Saxon created M&A deals worth over US$750 million across 113 countries. Produced several feature films and made-for-television movies, including Wonderfilm’s 2019 movie “Zombie Tidal Wave” for NBC/Universal’s SYFY.

17-Title Movie Slate — Greenlit

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few.

Some of the company’s most notable greenlit projects include the horror film “Amityville 1974,” slated for theatrical release in October 2020, and the action film “Inside Game” starring Tyrese Gibson, which will be released to theaters in fall 2020.

The company is also actively developing a number of other new IP projects, including a dramatic biographic feature titled “Life and Times of Steve McQueen,” a film adaptation of the bestselling novel “Merchant of Death” and a television series headed by “CSI: Crime Scene Investigation” creator Anthony Zuiker.

 

Potential for Breakout Success

Wonderfilm movies have the potential for millions of dollars in revenue from the kind of breakout success generated by films like “Saw” and “Get Out,” which would propel Wonderfilm and its revenue streams to a new level. Wonderfilm has several potential breakout films in its development/production queue.

Note: Potential breakout films are not factored into company’s revenue projections.

Base Hits and Home Runs

In tandem with its slate of high-profile films, Wonder?lm continues to finance, produce and deliver many profitable low-risk, lower-budget films that are base hits. Shaun Redick is a home run hitter, and his upcoming Wonderfilm projects are anticipated to be home run hits for the company, while base hits such as “Zombie Tidal Wave” provide a consistent source of revenue.

Recent Industry Breakout Films Include:

  • SAW – $1.2 million budget = $103.9 million in sales
  • Pulp Fiction – $8 million budget = $212 million in sales
  • My Big Fat Greek Wedding – $5 million budget = $250 million in sales
  • Lost in Translation – $4 million budget = $120 million in sales
  • Get Out – $4.5 million budget = $255.5 million sales (Shaun Redick)

Note: Revenue from most of Wonderfilm’s current slate will be recorded on the books in 2020 or 2021.

Recent Wonderfilm Releases

  • Aug. 17, 2019: Co-produced with NBC/Universal, “Zombie Tidal Wave” premièred on the SYFY channel to strong ratings.
  • Aug. 29, 2019: “The Fanatic” starring John Travolta opens in U.S. theaters.
  • Sept. 5, 2019: “Tammy’s Always Dying” premiers at Toronto Film Festival.
  • Nov. 8, 2019: “Primal” starring Nicolas Cage opens in U.S. theaters.

Wonderfilm Global Distribution

At the 2019 Cannes Film Festival, Wonderfilm officially launched Wonderfilm Global, a new film, television and media foreign sales/distribution joint venture with 101 Films and Paul McGowan.

Wonderfilm acquired 51% ownership in the joint venture structure and immediately began attaching its own productions to Wonderfilm Global. The joint venture represents a significant opportunity for Wonderfilm, changing how the company does business.

The intention behind Wonderfilm Global is to keep distribution margins in-house that previously went to other companies. Since most Wonderfilm movies are relatively low-risk and easy to sell because they feature desirable cast and genre, third-party distribution companies were previously earning approximately 10%, plus expenses, on Wonderfilm movies without any level of risk. Now, revenue is generated through presales of Wonder?lm projects and, at times, third-party films. The average Wonder?lm movie is pre-sold for $5million, garnering $500,000 to $750,000 per sale as a commission. These commissions now stay in-house with Wonder?lm Global, and the company expects to sell 10 to 12 third-party films between fall 2019 and fall 2020, generating roughly $6 million in commission income.

A further revenue source is generated from theatrical sales through a 50/50 upside split once the minimum sales threshold is met.

Wonder?lm Global has offices in Vancouver, Beverly Hills, London, Ireland, Seoul and China.

Wonderfilm Business Model

Wonderfilm productions are structured to begin generating a return to the company as soon as the camera starts rolling.

Return Before a Film is Delivered: Producer fee line items are included in each production budget. These range from $50,000 to $500,000, depending on the total budget, and are paid to Wonderfilm most commonly on the first day of principle photography.

Distribution: Wonderfilm Global charges sales and distribution fees within each production budget to cover its presale costs.

Note: Wonderfilm’s productions are all structured to minimize risk by matching budget to funds available.

Return After a Film is Delivered: Unsold presale territories are countries or territories left off of a film’s presale list, either for strategic reasons or because the broadcaster/distributor is waiting to see the completed film. These outside-the-budget distribution sales become Wonderfilm profit centers.

Sales overages once contracted presale threshold is surpassed.

The company’s film library grows with each new production, adding to future sales revenue. Depending on the agreement, exploitation rights for future worldwide sales return to Wonderfilm four or seven years after delivery. As of October 2019, Wonderfilm’s growing film library comprises 18 titles for future exploitation.

Note: The nature of the film business is that box office revenue lags production up to a couple of years.

$50 Million Wonderfilm Production Fund (WPF):

Wonderfilm is in the process of raising $50 million to establish a Wonderfilm Production Fund (WPF). WPF is designed to consolidate traditional production financing models into a single diversified, asset-backed debt instrument.

The WPF is a highly specialized investment vehicle with noncorrelated market returns normally reserved for institutional banks and specialty lenders, and it would pay 8% interest directly from each Wonderfilm movie or series budget and not from corporate funds. These same interest payments are already added to each production budget, as the company currently closes a separate financing for every film. The WPF would significantly streamline Wonderfilm’s production rate, adding revenue more quickly and broadening the yearly production slate.

For fund investors, the WPF is a dedicated production-financing vehicle designed to offer a risk-moderated approach to investing in film finance. The managed process provides structure and reassurance that are normally experienced only when working with an institutional lender that has a dedicated staff and resources.

All projects being financed are for Wonderfilm productions, with the fund collateral fully secured by receivables, including presale contracts, government incentives, or a guarantee from Wonderfilm for any unsecured amounts as may be permitted.

Wonderfilm Media Corporation (OTC: WDRFF), closed Friday's trading session at $0.1381, off by 1.3571%, on 29,800 volume with 7 trades. The average volume for the last 3 months is 63,090 and the stock's 52-week low/high is $0.075099997/$0.504400014.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

Fort Lauderdale, Florida-based VPR Brands (OTCQB: VPRB), a multivertical, tiered, technology holding company, is keeping a close eye on the 2020 presidential race to see where the contenders stand on cannabis issues. An article discussing the company reads, “Kevin Frija, the CEO of VPRB, commissioned a report (http://cnw.fm/ov0Ig) to outline where the 2020 presidential hopefuls stand on this critical issue. To view the full article, visit http://cnw.fm/UYQv5. Also today, the company was highlighted in a publication from HempWireNews, examining how in the 2019 Hemp and CBD Industry Factbook, Kristen Nichols writes that hemp is new, popular and has immense potential, but the course the hemp industry is taking is not yet clear. She likens the industry to a runner with brand new shoes and full of energy with no idea of the course.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit www.goldlinehemp.com for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Friday's trading session at $0.04, off by 20.00%, on 40,475 volume with 6 trades. The average volume for the last 3 months is 559,524 and the stock's 52-week low/high is $0.033799998/$0.119999997.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Technology and investment company SinglePoint (OTCQB: SING)was featured on this week’s episode of MoneyTV with Donald Baillargeon. The program is syndicated internationally and covers money-focused topics, featuring various companies and in-depth interviews with CEOs and executives that offer insights into operations and future outlooks. To view the full interview, visit http://cnw.fm/9xA9N. To view the full press release, visit http://cnw.fm/YK2qU.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Friday's trading session at $0.01152, off by 2.5381%, on 3,106,953 volume with 220 trades. The average volume for the last 3 months is 2,702,700 and the stock's 52-week low/high is $0.009999999/$0.028999999.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.